Olaf Christensen

About

• 14 years of pharmaceutical industry experience in the clinical development of oncology compounds • Over 5 years of clinical oncology experience in the treatment of cancer patients with solid tumors, leukemia, and lymphomas • Program Leader Gastric Ca, Prostate Ca, Paediatric Development, Ipilimumab Phase II-III • Global early clinical development project leader for cancer compounds, leading the early clinical development team including study teams in North America, Europe, and Asia • Responsible for conduct of oncology First in Patient studies, Proof of Concept studies, Phase I studies supporting NDA (QTc, food effect, DDI) • Experienced in IND and IMPD preparations • Representing early clinical development and clinical pharmacology in meetings with health authorities in the US and Europe • Covering translational medicine aspects in close contact with research and preclinical development functions • Strong academic research background with research experience in tumor immunology Specialties: Phase I-IV Clinical Development Oncology Translational Medicine Immuno Oncology

Experience

• Orum Therapeutics (Cambridge, Massachusetts, United States)
  • Chief Medical Officer
    Oct 2021 - Present · 4 yrs 9 mos

  • Chief Medical Officer
    Oct 2021 - Present · 4 yrs 9 mos

• EMD Serono, Inc. (Billerica Massachusetts)
  • Vice President
    Dec 2018 - Sep 2021 · 2 yrs 10 mos

    Head of Global Clinical Development Oncology I | Global Development | R&D

  • Executive Medical Director
    Nov 2015 - Nov 2018 · 3 yrs 1 mo

• Group Director at Bristol-Myers Squibb, Princeton, New Jersey
  Nov 2011 - Oct 2015 · 4 yrs

  Clinical Research Oncology

• Deputy Director of Oncology at Bayer Pharmaceuticals
  Mar 2004 - Nov 2011 · 7 yrs 9 mos

• attending physician, Clinic for Medical Oncology at University of Heidelberg
  Sep 1999 - Feb 2004 · 4 yrs 6 mos